SCHEMBL25241925

SCHEMBL25241925

CCn1nc(C)n(Cc2ccc(OC)cc2)c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 3/20 0.54
PDE1B Q01064 3/20 0.54
PDE1C Q14123 3/20 0.54
ALDH1A1 P00352 3/20 0.53
MAPT P10636 3/20 0.53
KDM4E B2RXH2 1/20 0.53
ALOX15 P16050 1/20 0.53
CMA1 P23946 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
RGS4 P49798 2/20 0.48
DCTPP1 Q9H773 2/20 0.47
P2RX4 Q99571 1/20 0.47
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
BRD9 Q9H8M2 1/20 0.46
GAA P10253 1/20 0.45
GFER P55789 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
RGS8 P57771 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27171716 0.75 PDE1B (0.50) PDE1APDE1BPDE1CALDH1A1MAPT
SCHEMBL13846106 0.74 LMNA (0.51) ALDH1A1MAPTMEN1KMT2ARGS4
SCHEMBL29965354 0.73 NPBWR1 (0.59) PDE1APDE1BPDE1CALDH1A1MAPT
SCHEMBL16544612 0.73 DCTPP1 (0.56) PDE1APDE1BPDE1CALDH1A1MAPT
SCHEMBL23663174 0.72 NPBWR1 (0.49) PDE1APDE1BPDE1CALDH1A1MAPT
SCHEMBL23671275 0.72 NPBWR1 (0.49) PDE1APDE1BPDE1CALDH1A1MAPT
SCHEMBL13903082 0.72 PPARA (0.67) RGS4
SCHEMBL11075143 0.72 L3MBTL1 (0.65) ALDH1A1MAPTMEN1KMT2ADCTPP1
SCHEMBL25274507 0.72 GAA (0.56) ALDH1A1MAPTKDM4EALOX15CMA1
SCHEMBL19434434 0.71 PDE1B (1.00) PDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454529-B2 Piperazine cyclic ureas Sironax Ltd. (KY) 2025-10-28 US disclosed
CN-115697991-B Piperazine cyclic ureas 维泰瑞隆有限公司 2024-11-22 CN disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 US disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 US disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 US disclosed
CN-115697991-A Piperazine cyclic ureas 维泰瑞隆有限公司 2023-02-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454529-B2 Piperazine cyclic ureas RIPK1, RIPK3, RIPK4 PDE1A 572/4885PDE1B 828/4885PDE1C 795/4885
US-20230203019-A1 Piperazine Cyclic Ureas RIPK1, RIPK3, RIPK4 PDE1A 572/4885PDE1B 828/4885PDE1C 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.